337 related articles for article (PubMed ID: 27255136)
41. Synthetic cannabis: adverse events reported to the New Zealand Pharmacovigilance Centre.
Robson H; Braund R; Glass M; Ashton J; Tatley M
Clin Toxicol (Phila); 2021 Jun; 59(6):472-479. PubMed ID: 33156704
[TBL] [Abstract][Full Text] [Related]
42. Synthetic Cannabinoid Receptor Agonists Detection Using Fluorescence Spectral Fingerprinting.
May B; Naqi HA; Tipping M; Scott J; Husbands SM; Blagbrough IS; Pudney CR
Anal Chem; 2019 Oct; 91(20):12971-12979. PubMed ID: 31580647
[TBL] [Abstract][Full Text] [Related]
43. Acute Toxicity Associated with Use of 5F-Derivations of Synthetic Cannabinoid Receptor Agonists with Analytical Confirmation.
Abouchedid R; Ho JH; Hudson S; Dines A; Archer JR; Wood DM; Dargan PI
J Med Toxicol; 2016 Dec; 12(4):396-401. PubMed ID: 27456262
[TBL] [Abstract][Full Text] [Related]
44. Safety issues concerning the medical use of cannabis and cannabinoids.
Ware MA; Tawfik VL
Pain Res Manag; 2005; 10 Suppl A():31A-7A. PubMed ID: 16237480
[TBL] [Abstract][Full Text] [Related]
45. Neurological soft signs in non-psychotic patients with cannabis dependence.
Dervaux A; Bourdel MC; Laqueille X; Krebs MO
Addict Biol; 2013 Mar; 18(2):214-21. PubMed ID: 21054691
[TBL] [Abstract][Full Text] [Related]
46. Spicing it up - synthetic cannabinoid receptor agonists and psychosis - a systematic review.
Hobbs M; Kalk NJ; Morrison PD; Stone JM
Eur Neuropsychopharmacol; 2018 Dec; 28(12):1289-1304. PubMed ID: 30454908
[TBL] [Abstract][Full Text] [Related]
47. Increases in synthetic cannabinoids-related harms: Results from a longitudinal web-based content analysis.
Lamy FR; Daniulaityte R; Nahhas RW; Barratt MJ; Smith AG; Sheth A; Martins SS; Boyer EW; Carlson RG
Int J Drug Policy; 2017 Jun; 44():121-129. PubMed ID: 28578250
[TBL] [Abstract][Full Text] [Related]
48. Neuropsychiatric Sequelae in Adolescents With Acute Synthetic Cannabinoid Toxicity.
Anderson SAR; Oprescu AM; Calello DP; Monte A; Dayan PS; Hurd YL; Manini AF;
Pediatrics; 2019 Aug; 144(2):. PubMed ID: 31285395
[TBL] [Abstract][Full Text] [Related]
49. Detection and quantitation of synthetic cannabinoid receptor agonists in infused papers from prisons in a constantly evolving illicit market.
Norman C; Walker G; McKirdy B; McDonald C; Fletcher D; Antonides LH; Sutcliffe OB; Nic Daéid N; McKenzie C
Drug Test Anal; 2020 Apr; 12(4):538-554. PubMed ID: 31944624
[TBL] [Abstract][Full Text] [Related]
50. A transnational perspective on the evolution of the synthetic cannabinoid receptor agonists market: Comparing prison and general populations.
Norman C; Halter S; Haschimi B; Acreman D; Smith J; Krotulski AJ; Mohr ALA; Logan BK; NicDaéid N; Auwärter V; McKenzie C
Drug Test Anal; 2021 Apr; 13(4):841-852. PubMed ID: 33463894
[TBL] [Abstract][Full Text] [Related]
51. Trends in hospital presentations following analytically confirmed synthetic cannabinoid receptor agonist exposure before and after implementation of the 2016 UK Psychoactive Substances Act.
Craft S; Dunn M; Vidler D; Officer J; Blagbrough IS; Pudney CR; Henderson G; Abouzeid A; Dargan PI; Eddleston M; Cooper J; Hill SL; Roper C; Freeman TP; Thomas SHL
Addiction; 2022 Nov; 117(11):2899-2906. PubMed ID: 35665553
[TBL] [Abstract][Full Text] [Related]
52. Synthetic cannabinoid receptor agonists are monoamine oxidase-A selective inhibitors.
Hindson SA; Andrews RC; Danson MJ; van der Kamp MW; Manley AE; Sutcliffe OB; Haines TSF; Freeman TP; Scott J; Husbands SM; Blagbrough IS; Anderson JLR; Carbery DR; Pudney CR
FEBS J; 2023 Jun; 290(12):3243-3257. PubMed ID: 36708234
[TBL] [Abstract][Full Text] [Related]
53. Modulation of human T-type calcium channels by synthetic cannabinoid receptor agonists in vitro.
Bladen C; Mirlohi S; Santiago M; Longworth M; Kassiou M; Banister S; Connor M
Neuropharmacology; 2021 Apr; 187():108478. PubMed ID: 33600843
[TBL] [Abstract][Full Text] [Related]
54. Characteristics of novel psychoactive substance exposures reported to New York City Poison Center, 2011-2014.
Palamar JJ; Su MK; Hoffman RS
Am J Drug Alcohol Abuse; 2016; 42(1):39-47. PubMed ID: 26678258
[TBL] [Abstract][Full Text] [Related]
55. Validation of the Prognostic Utility of the Electrocardiogram for Acute Drug Overdose.
Manini AF; Nair AP; Vedanthan R; Vlahov D; Hoffman RS
J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28159815
[TBL] [Abstract][Full Text] [Related]
56. Narrative Review of the Pharmacodynamics, Pharmacokinetics, and Toxicities of Illicit Synthetic Cannabinoid Receptor Agonists.
Lea Houston M; Morgan J; Kelso C
Mini Rev Med Chem; 2024; 24(1):92-109. PubMed ID: 37190813
[TBL] [Abstract][Full Text] [Related]
57. Health Risk Behaviors With Synthetic Cannabinoids Versus Marijuana.
Clayton HB; Lowry R; Ashley C; Wolkin A; Grant AM
Pediatrics; 2017 Apr; 139(4):. PubMed ID: 28289138
[TBL] [Abstract][Full Text] [Related]
58. Cannabinoid hyperemesis: marijuana puts patients in hot water.
Wallace D; Martin AL; Park B
Australas Psychiatry; 2007 Apr; 15(2):156-8. PubMed ID: 17464661
[TBL] [Abstract][Full Text] [Related]
59. Fourth Generation of Synthetic Cannabinoid Receptor Agonists: A Review on the Latest Insights.
Malaca S; Busardò FP; Nittari G; Sirignano A; Ricci G
Curr Pharm Des; 2022; 28(32):2603-2617. PubMed ID: 34781870
[TBL] [Abstract][Full Text] [Related]
60. [Synthetic Cannabinoid Receptor Agonist-Associated Psychotic Disorder: A Case Report].
Sönmez İ; Köşger F
Turk Psikiyatri Derg; 2016; 27(1):63-6. PubMed ID: 27369687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
